What are the medication instructions in the instructions for Pimitespib?

Pimitespib is an HSP90 inhibitor targeted drug, mainly used to treat gastric cancer and other solid tumors, especially for patients who have failed multiple lines of treatment in the past. In its drug instructions, the core contents such as usage, dosage recommendations, adverse reactions and precautions of the drug are clearly marked. The following is a summary of the main medication guidance:

First, in terms of recommended usage and dosage, according to the instructions for pimetibib, the recommended dose is 160mg once a day, taken orally on an empty stomach (at least 1 hour before a meal or at least 2hours), take the medicine 4 days a week (such as Monday, Tuesday, Thursday, and Friday), rest 3 days (such as Wednesday, Saturday, and Sunday), and every 28 days is a treatment cycle. During use, doctors will adjust the dosage based on the patient's tolerance and adverse reactions, such as reducing the dosage to 120 mg or 80 mg, or even suspending treatment.

Second, adverse reaction management is an important part of the instructions. Common adverse reactions of pimetibib include eye discomfort (such as blurred vision, dry eyes), fatigue, diarrhea, nausea, etc. A few patients may also experience abnormal liver function or elevated creatinine. The instructions recommend suspending the medication when a toxic reaction of Grade 3 or more severe occurs, resuming the medication as appropriate after the symptoms are relieved, and considering whether to reduce the dose or permanently discontinue the medication based on the degree of toxicity. Therefore, liver and kidney function and ophthalmic symptoms need to be closely monitored during use.

Third, in terms of medication guidance for special groups, the instructions for pimetibib indicate that direct use of the drug is not recommended for patients with mild to moderate impairment of liver function, and it is contraindicated for patients with severe liver function abnormalities; in addition, there is insufficient data to evaluate the safety of the drug in pregnant and lactating women, so use during pregnancy or lactation should be avoided. For elderly people over 65 years old, although there is no need to automatically adjust the dose, it is recommended to strengthen observation.

Fourth, in terms of combined medication and precautions, pimotebi is a CYP3A4 metabolized drug. The instructions recommend avoiding simultaneous use with strong CYP3A4 inhibitors or inducers (such as ketoconazole, rifampicin) to avoid affecting the blood concentration of the drug. At the same time, long-term combination with drugs that may affect gastric acid (such as proton pump inhibitors) should be avoided. During treatment, patients should avoid exposure to strong sunlight and pay attention to eye protection, such as using lubricating eye drops or wearing protective glasses.

Reference materials:https://www.mt-pharma.co.jp/e/company/rd/pipe/